Clinical Characteristics and Factors Associated with 30-Day Mortality in Patients with Methicillin-resistant Staphylococcal Pneumonia
DOI:
https://doi.org/10.31584/jhsmr.20241113Keywords:
pneumonia, methicillin-resistant Staphylococcus spp, 30-day mortality, risk facorsAbstract
Objective: We aimed to identify the risk factors associated with 30-day mortality in patients with methicillin-resistant Staphylococcus spp. (MRS) pneumonia.
Material and Methods: From March 2021 to March 2023, we conducted a prospective, observational study at Cho Ray Hospital, Viet Nam, in hospitalized patients aged ≥18 years with pneumonia due to MRS. To assess the risk factors for 30-day mortality, we performed univariable and multivariable logistic regression analyses.
Results: The 30-day mortality was 39.1% (36 out of 92 patients with MRS pneumonia). The risk factors for death within 30 days in cases with MRS pneumonia were severe pneumonia, being overweight, respiratory failure, shock, or having a medical device (a tracheostomy or endotracheal tube, a central venous catheter, a urinary catheter, or a nasogastric tube). The 30-day mortality increased proportionally with the number of risk factors.
Conclusion: Pre-existing factors were associated with the 30-day mortality risk of MRS pneumonia. Therefore, comprehensive therapy, including initial anti-MRS treatment, might be important for improving outcomes in patients with the studied risk factors.
References
Chansareewittaya K, Krajangcharoensakul S. The occurrence of antibiotic resistant bacteria contamination in sub-district health-promoting hospitals in Chiang Rai, Thailand. J Health Sci Med Res 2022;40:459-73. doi: 10.31584/jhsmr.2021857.
World Health Organization. WHO reveals leading causes of death and disability worldwide: 2000-2019. [homepage on the Internet]. Geneva: WHO; 2020 [cited 2024 Jan 18]. Available from: https://www.who.int/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019.
Kang SY, Cha WC, Yoo J, Kim T, Park JH, Yoon H, et al. Predicting 30-day mortality of patients with pneumonia in an emergency department setting using machine-learning models. Clin Exp Emerg Med 2020;7:197-205. doi: 10.15441/ceem.19.052.
Garcia-Vidal C, Fernández-Sabé N, Carratalà J, Díaz V, Verdaguer R, Dorca J. Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J 2008;32:733-9. doi: 10.1183/09031936.00128107.
Lee LN, Chou WR, Wang JY, Wang JY, Kuo YL, Chang CY, et al. Characteristics and local risk factors of community-acquired and health-care-associated Staphylococcus aureus pneumonia. Sci Rep 2022;12:18670. doi: 10.1038/s41598-022-23246-1.
Thabet N, Shindo Y, Okumura J, Sano M, Sakakibara T, Murakami Y et al. Clinical characteristics and risk factors for mortality in patients with community-acquired staphylococcal pneumonia. Nagoya J Med Sci 2022;84:247-59. doi: 10.18999/nagjms.84.2.247.
Tadros M, Williams V, Coleman BL, McGeer AJ, Haider S, Lee C, et al. Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitals. PLoS One 2013;8:e75171. doi: 10.1371/journal.pone.0075171.
Jones BE, Ying J, Stevens V, Haroldsen C, He T, Nevers M, et al. Empirical anti-MRSA vs standard antibiotic therapy and risk of 30-day mortality in patients hospitalized for pneumonia. JAMA Intern Med 2020;180:552-60. doi: 10.1001/jamainternmed.2019.7495.
Carretto E, Barbarini D, Couto I, De Vitis D, Marone P, Verhoef J, et al. Identification of coagulase-negative staphylococci other than Staphylococcus epidermidis by automated ribotyping. Clin Microbiol Infect 2005;11:177-84. doi: 10.1111/j.1469-0691.2004.01052.x.
Pfaller MA, Herwaldt LA. Laboratory, clinical, and epidemiological aspects of coagulase negative staphylococci. Clin Microbiol Rev 1988;1:281-99.
Demiselle J, Meyer P, Lavigne T, Kaurin J, Merdji H, Schenck M, et al. Clinical research in intensive care and sepsis - trial group for global eval-¨. Staphylococcus epidermidis bloodstream infections are a cause of septic shock in ICU patients. Int J Infect Dis 2023:00665-3. doi: 10.1016/j.ijid.2023.07.014.
National Healthcare Safety Network. Pneumonia (Ventila torassociated [VAP] and non-ventilator-associated Pneumonia [PNEU]) Events. [homepage on the Internet]. CDC; National Healthcare Safety Network; 2024 [cited 2024 Apr 3]. Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/6pscvapcurrent.pdf.
Mutonga DM, Mureithi MW, Ngugi NN, Otieno FCF. Bacterial isolation and antibiotic susceptibility from diabetic foot ulcers in Kenya using microbiological tests and comparison with RT-PCR in detection of S. aureus and MRSA. BMC Res Notes 2019;12:244. doi: 10.1186/s13104-019-4278-0.
Vardakas KZ, Matthaiou DK, Falagas ME. Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia. Eur Respir J 2009;34:1148-58. doi: 10.1183/09031936.00041009.
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K,et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the american thoracic society and infectious diseases society of America. Am J Respir Crit Care Med 2019;200:e45-67. doi: 10.1164/rccm.201908-1581ST.
Li R, Tang H, Xu H, Cui K, Li S, Shen J. Effect on 30-day mortality and duration of hospitalization of empirical antibiotic therapy in CRGNB-infected pneumonia. Ann Clin Microbiol Antimicrob 2021;20:15. doi: 10.1186/s12941-021-00421-2.
Shime N, Saito N, Bokui M, Sakane N, Kamimura M, Shinohara T, et al. Clinical outcomes after initial treatment of methicillin-resistant Staphylococcus aureus infections. Infect Drug Resist 2018;6:1073-81. doi: 10.2147/IDR.S159447.
Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Goto Y, et al. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study. Lancet Infect Dis 2015;15:1055-65. doi: 10.1016/S1473-3099(15)00151-6.
Becker K, Heilmann C, Peters G. Coagulase-Negative Staphylococci. Clinical Microbiology Reviews 2014:870-926. doi: 10.1128/CMR.00109-13.
Michels R, Last K, Becker SL, Papan C. Update on Coagulase-Negative Staphylococci—What the Clinician Should Know. Microorganisms 2021:9:830.
Michalik M, Samet A, Podbielska-Kubera A, Savini V, Międzobrodzki J, Kosecka-Strojek M, et al. Coagulase-negative staphylococci (CoNS) as a significant etiological factor of laryngological infections: a review. Ann Clin Microbiol Antimicrob 2020:19:26. doi: 10.1186/s12941-020-00367-x.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637. doi: 10.1097/CCM.0b013e31827e83af.
Ju G, Zhang Y, Ye C, Liu Q, Sun H, Zhang Z, et al. Comparative effectiveness and safety of six antibiotics in treating MRSA infections: a network meta-analysis. Int J Infect Dis 2024;146: 107109. doi: 10.1016/j.ijid.2024.107109.
Brown NM, Goodman AL, Horner C, Jenkins A, Brown EM. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. JAC Antimicrob Resist 2021;3:dlaa114. doi: 10.1093/jacamr/dlaa114.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
